Apotex Seeks To Dance Quick Step In Biosimilars Appeal
This article was originally published in Scrip
Apotex Inc. revealed in court documents late on Dec. 14 that it anticipates the FDA to make a decision on the company's 351(k) application for its pegfilgrastim biosimilar "within the next several months" – providing some insight into the status of the product, whose verdict was due nearly two months ago and for which the firm has kept a tight lip.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.